Business Context and Reporting Period
This Form 8-K was filed by Intelligent Bio Solutions Inc. on September 25, 2024. The report discloses a specific corporate governance event regarding executive compensation rather than routine financial performance.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the valuation of specific equity awards:
- CEO Award Value: $76,400
- CFO Award Value: $65,895
- Total Award Value: $142,295
Material Changes
The material change reported is the grant of special one-time equity awards to senior executives:
- Harry Simeonidis (CEO): Received 40,000 shares of fully vested common stock.
- Spiro Sakiris (CFO): Received 34,500 shares of fully vested common stock.
- Valuation Basis: Awards were valued based on the closing price of the Company's common stock on September 25, 2024.
Management Commentary and Context
The Compensation Committee, composed entirely of independent directors, authorized these awards in connection with the Company's 2024 compensation analysis and evaluation. The filing does not contain forward-looking guidance, risk factors, or contingencies beyond the standard disclosure of the compensation event.
Investor Verification Checklist
- Verify the closing stock price of INBS on September 25, 2024, to confirm the per-share valuation used for the awards.
- Review the Company's 2024 compensation analysis to understand the rationale for these special one-time awards.
- Check subsequent filings for the impact of these grants on the Company's total share count and dilution.
- Confirm that the Compensation Committee's independence status remains current.